Amgen has finished building its new $200 million next-generation biomanufacturing facility in Singapore, ushering in a new era for the company. The plant's features a continuous manufacturing model that replaces biotech's traditional batch processing. Robert Bradway, Amgen's Chairman and CEO, earlier claimed the technology cuts costs dramatically: capital costs by 75%, operating expenses by 67% and manufacturing time by 50% -- overall, continuous manufacturing reduces the cost per gram of protein by 60%, he said.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
